SLN Stock Price | Silence Therapeutics PLC P/E, Revenue, EPS, & Forecasts

Silence Therapeutics PLC • SLN

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Silence Therapeutics PLC

Ticker

SLN

Trading on

NASDAQ

ISIN

US82686Q1013

Industry

Biotechnology

Sector

Healthcare

CEO

Craig A. Tooman M.B.A.

Headquarters

72 Hammersmith Road, London, undefined, United Kingdom, W14 8TH

Employees

116

Website

silence-therapeutics.com

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Metrics

BasicAdvanced

Market cap

$261M

P/E ratio

EPS

-$1.53

Dividend Yield

0.00%

Beta

1.41

Forward P/E ratio

EBIDTA

$-71.6M

Ex dividend date

Price & volume

Market cap

$261M

Average daily volume

0.1M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

9.41

Price to book

5.78

Earnings

EPS

-$1.53

EPS estimate (current quarter)

-$0.42

EPS estimate (next quarter)

-$0.43

EBITDA

$-71.6M

Revenues (TTM)

$27.7M

Revenues per share (TTM)

$0.59

Technicals

Beta

1.41

52-week High

$22.47

52-week Low

$1.97

50-day moving average

$4.86

200-day moving average

$8.01

Short ratio

6.1

Short %

2.53%

Management effectiveness

ROE (TTM)

-53.13%

ROA (TTM)

-20.96%

Profit margin

-258.21%

Gross profit margin

$18.6M

Operating margin

-18,119.72%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

-99.10%

Share stats

Outstanding Shares

47.2M

Float

76M

Insiders %

24.38%

Institutions %

48.83%

Analyst Insights & forecasts

86% Buy

0% Hold

14% Sell

Based on information from 7 analysts.

Average price target

$32.37

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.43

-$0.11

-273.54%

Q2 • 24Missed

-$0.73

-$0.13

-477.72%

Q3 • 24Missed

$0.17

-$0.25

169.33%

Q4 • 24Beat

-$0.20

-$0.40

50.00%

Q1 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$24.3M

$14.2M

58.26%

Q4 • 24

$0.1M

$-28.5M

-20,091.55%

Q1 • 25

-99.42%

-301.28%

-34,583.99%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$203M

$68.6M

33.86%

Q4 • 24

$185M

$-72.6M

-39.16%

Q1 • 25

-8.56%

-205.75%

-215.64%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-24.9M

$68.1M

$-8.3M

$-24.9M

Q4 • 24

$-12.3M

$-44.4M

$0M

$-12.3M

Q1 • 25

-50.50%

-165.14%

-100.17%

-50.59%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Silence Therapeutics PLC share?

Silence Therapeutics PLC shares are currently traded for undefined per share.

How many shares does Silence Therapeutics PLC have?

Silence Therapeutics PLC currently has 47.2M shares.

Does Silence Therapeutics PLC pay dividends?

No, Silence Therapeutics PLC doesn't pay dividends.

What is Silence Therapeutics PLC 52 week high?

Silence Therapeutics PLC 52 week high is $22.47.

What is Silence Therapeutics PLC 52 week low?

Silence Therapeutics PLC 52 week low is $1.97.

What is the 200-day moving average of Silence Therapeutics PLC?

Silence Therapeutics PLC 200-day moving average is $8.01.

Who is Silence Therapeutics PLC CEO?

The CEO of Silence Therapeutics PLC is Craig A. Tooman M.B.A..

How many employees Silence Therapeutics PLC has?

Silence Therapeutics PLC has 116 employees.

What is the market cap of Silence Therapeutics PLC?

The market cap of Silence Therapeutics PLC is $261M.

What is the P/E of Silence Therapeutics PLC?

The current P/E of Silence Therapeutics PLC is null.

What is the EPS of Silence Therapeutics PLC?

The EPS of Silence Therapeutics PLC is -$1.53.

What is the PEG Ratio of Silence Therapeutics PLC?

The PEG Ratio of Silence Therapeutics PLC is null.

What do analysts say about Silence Therapeutics PLC?

According to the analysts Silence Therapeutics PLC is considered a buy.